Sun, Sep 21, 2014, 5:04 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Corinthian Colleges Inc. Message Board

gladpick 10 posts  |  Last Activity: Sep 15, 2014 8:49 AM Member since: Jan 24, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    steady

    by usingaliase Sep 12, 2014 9:45 AM
    gladpick gladpick Sep 15, 2014 8:49 AM Flag

    Cow,
    I totally agree with your assessment of HR. He and the teams he recruits to help him have made several blunders which would have caused other BOD to fire such CEO had it happened to their companies. Unfortunately most members of NKTR BOD are HR's stooges IMHO.

  • Reply to

    pipeline

    by papaalien2000 Aug 4, 2014 10:13 AM
    gladpick gladpick Aug 5, 2014 9:51 AM Flag

    "The most recent Form 10-Q mentions pipeline including oncology, MS, and flu drug VX-787 and its backup VX-353. "

    That is good. However, most people do not read the 10-Q reports. Jeff or the medical/scientific officers should mention the compounds in the pipeline and elaborate with some details during their presentation. I understand that they want to end the conference call within one hour and that may may the reason they limit their presentation mostly to CF. It seems to me they should not mind stretching the call a bit longer than one hour and cover the pipeline.

  • Reply to

    pipeline

    by papaalien2000 Aug 4, 2014 10:13 AM
    gladpick gladpick Aug 4, 2014 12:55 PM Flag

    I posted similar complaint on this board a while ago.

    Effective people are capable of being multitask. I am wondering if Jeff Leiden and his team are multitask types. All they talk about is CF, CF, CF. What about the pipeline Jeff? What happens when competition will come up with a better CF drug. We could go back to an annual loss just like when Incivek hit the dust!

  • EARNINGS LOSS OF $.26 VS ANALYSTS' ESTIMATE OF A LOSS OF $.37.

    REVENUE OF $33.9 M VS ANALYSTS' ESTIMATE OF $19.76M

  • you can find it on seekingalpha.

  • Reply to

    time to load up

    by gladpick Jul 8, 2014 2:34 PM
    gladpick gladpick Jul 9, 2014 9:14 PM Flag

    " I think a lot of people might panic if FDA delivers bad news for Relistor, and think 118/Naloxegol/Movantik is in the same boat"

    I guess you are implying that the FDA would announce its final decision on Relistor BEFORE announcing it about Naloxegol.
    Is it known the dates that FDA would release its decision on each one of the drugs the advisory committee voted on in june 10-11? Have these dates been announced by the FDA?

  • Is a joke. Rated VRTX a sell when it was trading in high 50's, low 60's. Now that it is in the upper 90's it rates it a hold. A very good rating system if you love losing money!

  • gladpick by gladpick Jul 8, 2014 2:34 PM Flag

    Sold some of my VRTX shares and bought a big chunk of more NKTR. it may go lower but it is very hard to catch all of one's investments at the bottom. Good luck to all longs.

  • Reply to

    History depends on the circumstances

    by qdelfan Jun 29, 2014 6:54 PM
    gladpick gladpick Jun 30, 2014 8:38 AM Flag

    Geoff Porges should be fired by Sanford B. He slammed VRTX drugs with no viable or reliable reason and by ignoring the phase 2 data. It seems to me if in fact some of SB clients and institutions/hedge funds actually listened to this bozo they must have lost tons of money and must be mad as hell.

  • Reply to

    A post from facebook:

    by gladpick Jun 6, 2014 11:24 AM
    gladpick gladpick Jun 23, 2014 6:07 PM Flag

    The report I posted was a family member of the patient, not the patient himself (I believe it was a father). Any way how are they going to trace the father of a patient and then also kick him out of the tral if his father was the one who reported his observation of his son?

COCO
0.1588+0.0488(+44.36%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.